Semaglutide

Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1) designed to activate the GLP-1 receptor with a much longer half-life than native GLP-1. It is one of the better-characterized peptide therapeutics and has substantial randomized clinical trial data in metabolic disease.

Semaglutide is derived from the endogenous incretin peptide GLP-1 with amino-acid substitutions and fatty-acid acylation that increase albumin binding and prolong circulation time. This design strategy was developed to support once-weekly dosing rather than the rapid degradation seen with native GLP-1.

The primary mechanism is GLP-1 receptor agonism. In clinical and translational studies, this is associated with glucose-dependent insulin effects, reduced glucagon signaling, delayed gastric emptying, and reduced energy intake. These are receptor-mediated pharmacology findings; they do not imply identical clinical response across all populations.

Clinically studied. Large randomized trials in obesity and cardiometabolic risk populations have reported clinically meaningful effects on body weight and cardiovascular outcomes in selected groups. Evidence quality is high for approved indications, but extrapolation to unrelated uses is not supported.

• Obesity and long-term weight management
• Type 2 diabetes and glycemic outcomes
• Cardiovascular outcomes in people with overweight or obesity and established cardiovascular disease
• Broader cardiometabolic risk modification

Despite robust trial data, there are still limitations: heterogeneous trial populations, adverse-effect-related discontinuation, and uncertainty about long-term outcomes after treatment cessation. Mechanistic plausibility does not replace indication-specific evidence, and off-label claims should be interpreted cautiously.

• Lau J, Bloch P, Schaffer L, et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. Journal of Medicinal Chemistry. 2015;58(18):7370-7380. doi:10.1021/acs.jmedchem.5b00726.
• Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183.
• Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023;389(24):2221-2232. doi:10.1056/NEJMoa2307563.